Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Yuko Omori

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0004-8285-5340; OpenAlex author ID A5035197786. Sources: OpenAlex.

Their work

Papers
11 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
72
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 3 papers

Papers 11

  1. Transcriptional regulation of ETV5 by mitogen-activated protein kinase via ETS-1 in human pancreatic cancer cells. Co-author DOI 10.1038/s41598-025-97166-1↗
  2. Clinicopathological Relevance of SMAD4 and RUNX3 in Patients With Resected Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000002429↗
  3. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. First author DOI 10.1097/sla.0000000000006444↗
  4. GATA6 and CK5 Stratify the Survival of Patients With Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy. First author DOI 10.1016/j.modpat.2023.100102↗
  5. Co-occurring IPMN and pancreatic cancer: the same or different? An overview from histology to molecular pathology. Co-author DOI 10.1136/jcp-2023-209012↗
  6. Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9. Co-author DOI 10.1245/s10434-022-11630-0↗
  7. A deep learning model to detect pancreatic ductal adenocarcinoma on endoscopic ultrasound-guided fine-needle biopsy. Co-author DOI 10.1038/s41598-021-87748-0↗
  8. Genetic Tracing of Clonal Expansion and Progression of Pancreatic Ductal Adenocarcinoma: A Case Report and Multi-Region Sequencing Analysis. Co-author DOI 10.3389/fonc.2020.00728↗
  9. Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features. Co-author DOI 10.1053/j.gastro.2018.10.029↗
  10. Genetic analysis of postoperative recurrence of pancreatic cancer potentially owing to needle tract seeding during EUS-FNB. Co-author DOI 10.1055/a-1034-7700↗
  11. Utility of "liquid biopsy" using pancreatic juice for early detection of pancreatic cancer. Co-author DOI 10.1055/a-0721-1747↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Furukawa · 9 shared papers, 2019–2025 · strength 1.49
  2. Yusuke Mizukami · 7 shared papers, 2018–2025 · strength 0.73
  3. Michiaki Unno · 3 shared papers, 2023–2025 · strength 0.53
  4. Katsuya Hirose · 2 shared papers, 2025 · strength 0.49
  5. Takashi Kokumai · 2 shared papers, 2023–2025 · strength 0.38
  6. Kei Nakagawa · 2 shared papers, 2023–2025 · strength 0.38
  7. Masamichi Mizuma · 2 shared papers, 2023–2025 · strength 0.38
  8. Masakazu Yamamoto · 1 shared paper, 2025 · strength 0.33
  9. Atsushi Masamune · 2 shared papers, 2023–2025 · strength 0.31
  10. Junpei Sasajima · 4 shared papers, 2018–2020 · strength 0.30
  11. Toshikatsu Okumura · 4 shared papers, 2018–2020 · strength 0.30
  12. Satoshi Hirano · 2 shared papers, 2022–2025 · strength 0.27
  13. Claudio Luchini · 1 shared paper, 2023 · strength 0.26
  14. Aldo Scarpa · 1 shared paper, 2023 · strength 0.26
  15. Tetsuhiro Okada · 3 shared papers, 2018–2020 · strength 0.23
  16. Yuriko Saiki · 1 shared paper, 2025 · strength 0.22
  17. Aya Noguchi · 1 shared paper, 2025 · strength 0.22
  18. Tomohiko Ishikawa · 1 shared paper, 2025 · strength 0.22
  19. Shinya Tanaka · 2 shared papers, 2019–2020 · strength 0.16
  20. Tamotsu Kuroki · 1 shared paper, 2025 · strength 0.16
  21. Hisato Igarashi · 1 shared paper, 2025 · strength 0.16
  22. Kenichi Hakamada · 1 shared paper, 2025 · strength 0.16
  23. Sohei Satoi · 1 shared paper, 2025 · strength 0.16
  24. Masayuki Furukawa · 1 shared paper, 2025 · strength 0.16
  25. Motokazu Sugimoto · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.